A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

LESSONS LEARNED: Our results highlight additional toxicities of dual PI3K/mTOR inhibition in the clinical setting that were unforeseen from preclinical models. Because of toxicity and lack of efficacy, BEZ235 should not be further developed in the current formulation for patients with renal cell car...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Carlo, Maria I., Molina, Ana M., Lakhman, Yulia, Patil, Sujata, Woo, Kaitlin, DeLuca, John, Lee, Chung-Han, Hsieh, James J., Feldman, Darren R., Motzer, Robert J., H. Voss, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943396/
https://ncbi.nlm.nih.gov/pubmed/27286790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0145
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados